Abstract
Objectives: Pain still afflicts most cancer patients, mainly in the metastatic phases, and under-treatment is well documented. Transdermal delivery systems (TDS) containing fentanyl or buprenorphine could potentiality have advantages over oral and parenteral routes, but evidence from comparative trials are scanty. In the framework of a wider initiative, an Outcome Research Study was carried out in Italy in 2006 to evaluate the effects of various analgesic options, particularly buprenorphine TDS. Methods: This is a multicenter, open-label, prospective, nonrandomized study. Data were collected using a web-based standardized system, with a follow-up up of to 3 months. Pain intensity, the primary outcomes of the study, was measured using 11-point numerical rating scales from the Brief Pain Inventory. Results: One-hundred ten centers recruited 1801 cases, most of which (60%) were receiving a strong opioid at the time of inclusion. Of these, 257 had TDS buprenorphine as first choice. Of the remaining 709 patients who at the time of inclusion were not on a strong opioid, 325 changed to a strong opioid and in 43% it was TDS buprenorphine. During the follow-up, physicians had to increase the dosage to control pain (average increase between 16% and 17%). About 34% of patients had an improvement of at least 2 points in worst pain, 15% had a 20% improvement in pain relief, and 40% in satisfaction. Results were in line with those of patients receiving other World Health Organization-level III opioids. CONCLUSIONS: Despite the limitations owing to the observational design, these findings may be useful to clinicians to judge the value of the drug under evaluation better and to help researchers design further comparative studies.
| Original language | English |
|---|---|
| Pages (from-to) | 671-682 |
| Number of pages | 12 |
| Journal | Clinical Journal of Pain |
| Volume | 25 |
| Issue number | 8 |
| DOIs | |
| Publication status | Published - Oct 2009 |
Fingerprint
Keywords
- Buprenorphine
- Cancer pain
- Opioids
- Outcome Research
ASJC Scopus subject areas
- Anesthesiology and Pain Medicine
- Clinical Neurology
Cite this
Effects of transdermal buprenorphine on patients-reported outcomes in cancer patients : Results from the cancer pain outcome research (CPOR) study group. / Apolone, Giovanni; Corli, Oscar; Negri, Emanuele; Mangano, Simone; Montanari, Mauro; Greco, Maria Teresa.
In: Clinical Journal of Pain, Vol. 25, No. 8, 10.2009, p. 671-682.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Effects of transdermal buprenorphine on patients-reported outcomes in cancer patients
T2 - Results from the cancer pain outcome research (CPOR) study group
AU - Apolone, Giovanni
AU - Corli, Oscar
AU - Negri, Emanuele
AU - Mangano, Simone
AU - Montanari, Mauro
AU - Greco, Maria Teresa
PY - 2009/10
Y1 - 2009/10
N2 - Objectives: Pain still afflicts most cancer patients, mainly in the metastatic phases, and under-treatment is well documented. Transdermal delivery systems (TDS) containing fentanyl or buprenorphine could potentiality have advantages over oral and parenteral routes, but evidence from comparative trials are scanty. In the framework of a wider initiative, an Outcome Research Study was carried out in Italy in 2006 to evaluate the effects of various analgesic options, particularly buprenorphine TDS. Methods: This is a multicenter, open-label, prospective, nonrandomized study. Data were collected using a web-based standardized system, with a follow-up up of to 3 months. Pain intensity, the primary outcomes of the study, was measured using 11-point numerical rating scales from the Brief Pain Inventory. Results: One-hundred ten centers recruited 1801 cases, most of which (60%) were receiving a strong opioid at the time of inclusion. Of these, 257 had TDS buprenorphine as first choice. Of the remaining 709 patients who at the time of inclusion were not on a strong opioid, 325 changed to a strong opioid and in 43% it was TDS buprenorphine. During the follow-up, physicians had to increase the dosage to control pain (average increase between 16% and 17%). About 34% of patients had an improvement of at least 2 points in worst pain, 15% had a 20% improvement in pain relief, and 40% in satisfaction. Results were in line with those of patients receiving other World Health Organization-level III opioids. CONCLUSIONS: Despite the limitations owing to the observational design, these findings may be useful to clinicians to judge the value of the drug under evaluation better and to help researchers design further comparative studies.
AB - Objectives: Pain still afflicts most cancer patients, mainly in the metastatic phases, and under-treatment is well documented. Transdermal delivery systems (TDS) containing fentanyl or buprenorphine could potentiality have advantages over oral and parenteral routes, but evidence from comparative trials are scanty. In the framework of a wider initiative, an Outcome Research Study was carried out in Italy in 2006 to evaluate the effects of various analgesic options, particularly buprenorphine TDS. Methods: This is a multicenter, open-label, prospective, nonrandomized study. Data were collected using a web-based standardized system, with a follow-up up of to 3 months. Pain intensity, the primary outcomes of the study, was measured using 11-point numerical rating scales from the Brief Pain Inventory. Results: One-hundred ten centers recruited 1801 cases, most of which (60%) were receiving a strong opioid at the time of inclusion. Of these, 257 had TDS buprenorphine as first choice. Of the remaining 709 patients who at the time of inclusion were not on a strong opioid, 325 changed to a strong opioid and in 43% it was TDS buprenorphine. During the follow-up, physicians had to increase the dosage to control pain (average increase between 16% and 17%). About 34% of patients had an improvement of at least 2 points in worst pain, 15% had a 20% improvement in pain relief, and 40% in satisfaction. Results were in line with those of patients receiving other World Health Organization-level III opioids. CONCLUSIONS: Despite the limitations owing to the observational design, these findings may be useful to clinicians to judge the value of the drug under evaluation better and to help researchers design further comparative studies.
KW - Buprenorphine
KW - Cancer pain
KW - Opioids
KW - Outcome Research
UR - http://www.scopus.com/inward/record.url?scp=70349672833&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=70349672833&partnerID=8YFLogxK
U2 - 10.1097/AJP.0b013e3181a38f9d
DO - 10.1097/AJP.0b013e3181a38f9d
M3 - Article
C2 - 19920716
AN - SCOPUS:70349672833
VL - 25
SP - 671
EP - 682
JO - Clinical Journal of Pain
JF - Clinical Journal of Pain
SN - 0749-8047
IS - 8
ER -